Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a talking AI coach teach your brain to handle stress?

NCT ID NCT07840469

Symptom relief Sponsor: Hamid Reza Marateb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers are testing a Persian-language AI chatbot that walks adults through cognitive behavioral therapy exercises for mild to moderate stress. The pilot enrolls 120 people aged 18 to 45 and randomly assigns them to the chatbot, mental health education content, or a waitlist for 14 days. The team measures changes in perceived stress and checks whether the chatbot is feasible, acceptable, and safe. A separate part of the study collects voice recordings to train a stress-detection model, but that model does not influence the chatbot or any participant's care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A Persian-language AI chatbot that delivers cognitive behavioral therapy exercises for stress
What this could lead to
If it works, this could point toward a low-cost, widely available digital tool for people who want help managing everyday stress.
What could go wrong
This is a small, short pilot with only 14 days of intervention, so any stress improvements may be modest or fade. Chatbot support may not suit everyone, and the voice-analysis component is separate research that does not guide care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 45 years * Mild or moderate perceived stress based on the Perceived Stress Scale-10 (PSS-10) screening assessment * Ability to use a smartphone * Access to the internet during the study period * Ability and willingness to provide electronic informed consent * Willingness to participate in study assessments and complete the required study procedures Exclusion Criteria: * Severe perceived stress at the initial screening assessment * Active suicidal ideation or risk of self-harm * Acute psychological crisis requiring immediate professional intervention * Active psychosis * Active mania * Severe substance use disorder * Psychiatric hospitalization in recent months * Initiation of a new psychiatric medication or change in the dose of a psychiatric medication within the previous four weeks * Concurrent participation in intensive psychotherapy or another intensive psychological intervention * Any mental health condition requiring immediate specialist evaluation or treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Perceived stress are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Stress, Psychological

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Perceived stress Psychological stress

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Isfahan University of Medical Sciences

    Isfahan, Isfahan, Iran

More trials for these conditions

Other studies related to the condition(s) this trial covers.